Gapping up
In reaction to strong earnings/guidance:
- VICR +21.8%, WGO +13.4%, NFLX +11% (also guided for Q4; sees subscriber additions above estimates), HOPE +8.6% (bad trade) LRCX +6.8% (also guided Q2 EPS above consensus), UAL +5.9% (also raised low end of EPS guidance for FY18), MTG +4.7%, FULT +2.3%, LTXB +2.2% (also increased quarterly dividend to $0.22/share), CREE +2.1% (also signed agreement valued at $85 mln to supply Wolfspeed silicon carbide wafers), PSO +2.1%, ASML +1.9%, CSX +1.7% (also updated FY18 revenue guidance on call), MTB +1.5%, USB +0.9%
Other news:
- ROKU +3.5% (to resume sales of Roku devices in Mexico)
- AMAT +3.3% (following upbeat first quarter report from Lam Research)
- AGLE +3.1% (announces 'new positive' interim clinical data from ongoing Phase 1/2 trial of pegzilarginase in patients with the rare genetic disease Arginase 1 Deficiency
- JBLU +2% (following guidance from United Continental)
- LUV +2% (following guidance from United Continental)
Analyst comments:
- AZRX +8% (initiated with an Outperform at Oppenheimer)
- AAL +4.1% (upgraded to Buy from Hold at Deutsche Bank)
- NTAP +3.3% (added to Conviction Buy List at Goldman)
- AKRX +3.3% (upgraded to Overweight from Neutral at Piper Jaffray)
- DAL +3.2% (upgraded to Buy from Hold at Deutsche Bank)
- PSTG +2.1% (upgraded to Neutral from Sell at Goldman)
- WDAY +2.1% (upgraded to Outperform from Mkt Perform at Bernstein)
- MDB +1.1% (initiated with a Outperform at Oppenheimer)
- ANET +1% (upgraded to Outperform from Market Perform at BMO Capital Markets)
![]()